Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

NCT01332279 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Pharmaceutical co. withdrew support. Study was never activated and did not accrue any patients.

Conditions

Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Larynx
Recurrent Verrucous Carcinoma of the Oral Cavity
Salivary Gland Squamous Cell Carcinoma
Tongue Cancer

Interventions

DRUG: everolimus
DRUG: erlotinib hydrochloride
PROCEDURE: biopsy
OTHER: laboratory biomarker analysis
OTHER: immunohistochemistry staining method
GENETIC: polyacrylamide gel electrophoresis
OTHER: pharmacological study
RADIATION: external beam radiation therapy
GENETIC: microarray analysis

Sponsor

Fox Chase Cancer Center